Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexavalent norovirus vaccine (Grand Theravac Life Sciences)
- Development stage
- Unknown
- Lead developer
- Grand Theravac Life Science Nanjing
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The hexavalent norovirus vaccine is a recombinant virus-like particle (VLP) vaccine developed by Grand Theravac Life Sciences (Nanjing) Co., Ltd. for the prevention of norovirus-induced acute gastroenteritis. Produced using the *Hansenula polymorpha* (Hansen yeast) expression system, the vaccine consists of VLPs that mimic the structure of six different norovirus strains/genotypes but lack viral genetic material, rendering them non-infectious. By targeting multiple genotypes, the vaccine aims to provide broad protective immunity against the genetically diverse norovirus strains responsible for global outbreaks. It has progressed to Phase 2 clinical development following safety and immunogenicity evaluations in Phase 1 trials involving participants aged 6 months and older.
- Other names
- Recombinant hexavalent norovirus VLP vaccineHexavalent norovirus vaccine
02
Targets
NV (Norovirus)Norovirus VP1
Beyond the preview
Go deeper on Hexavalent norovirus vaccine (Grand Theravac Life Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hexavalent norovirus vaccine (Grand Theravac Life Sciences).